Canadian Agency Give Positive Opinion for Reimbursement of GIVLAARI for AHP
GIVLAARI has already received approval for the treatment of acute hepatic porphyria (AHP) in Canada, according to an article from Nasdaq. Now, the Canadian Agency for Drugs and Technologies in…